Transmarket Holdings LP Purchases 138,110 Shares of BioLife Solutions, Inc. $BLFS

Key Points

• Transmarket Holdings LP acquired 138,110 shares of BioLife Solutions valued at approximately $5.4 million, representing 0.28% of the company and 3% of the fund’s portfolio.
• Institutional ownership remains high at 93.24%, with several major investors recently increasing or initiating positions in BioLife Solutions.
• Despite quarterly earnings and revenue exceeding analyst expectations, analysts remain cautious: the stock has a consensus “Hold” rating and an average price target of $31.38, below its reported $38.61 share price.

Transmarket Holdings LP acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 138,110 shares of the medical equipment provider's stock, valued at approximately $5,366,000. BioLife Solutions makes up about 3.0% of Transmarket Holdings LP's holdings, making the stock its 6th biggest position. Transmarket Holdings LP owned 0.28% of BioLife Solutions as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of America Corp DE lifted its stake in BioLife Solutions by 73.4% during the 1st quarter. Bank of America Corp DE now owns 904,103 shares of the medical equipment provider's stock worth $17,250,000 after acquiring an additional 382,776 shares in the last quarter. Granahan Investment Management LLC grew its position in BioLife Solutions by 49.7% in the 1st quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider's stock valued at $13,777,000 after acquiring an additional 239,701 shares in the last quarter. Ranger Investment Management L.P. purchased a new stake in BioLife Solutions during the second quarter worth about $6,736,000. Bank of New York Mellon Corp acquired a new stake in shares of BioLife Solutions during the second quarter worth about $6,470,000. Finally, Summit Creek Advisors LLC acquired a new stake in shares of BioLife Solutions during the second quarter worth about $5,099,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $38.61 on Thursday. BioLife Solutions, Inc. has a 52 week low of $17.86 and a 52 week high of $39.76. The stock has a market capitalization of $1.89 billion, a PE ratio of 33.28 and a beta of 1.82. The firm has a 50 day moving average of $37.46 and a two-hundred day moving average of $27.81.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.88. The company had revenue of $28.47 million for the quarter, compared to the consensus estimate of $27.80 million. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. On average, equities research analysts expect that BioLife Solutions, Inc. will post 0.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Jefferies Financial Group lowered shares of BioLife Solutions from a "buy" rating to a "hold" rating and raised their price objective for the company from $30.00 to $31.00 in a research note on Thursday, July 23rd. William Blair set a $31.00 target price on shares of BioLife Solutions in a research note on Thursday, July 23rd. Stephens lowered shares of BioLife Solutions from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $32.00 to $31.00 in a report on Monday, July 27th. HC Wainwright lowered shares of BioLife Solutions from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $32.00 to $31.00 in a report on Thursday, July 23rd. Finally, Maxim Group cut shares of BioLife Solutions from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $31.38.

About BioLife Solutions

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company's portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.